Literature DB >> 27641758

Gene expression profiling of CD8+ T cells induced by ovarian cancer cells suggests a possible mechanism for CD8+ Treg cell production.

Meng Wu1,2, Jianfang Lou1,2, Shuping Zhang1,2, Xian Chen1,2, Lei Huang1,2, Ruihong Sun1,2, Peijun Huang1,2, Shiyang Pan1,2, Fang Wang3,4.   

Abstract

OBJECTIVES: The aim of this study was to investigate a possible mechanism of CD8+ regulatory T-cell (Treg) production in an ovarian cancer (OC) microenvironment.
MATERIALS AND METHODS: Agilent microarray was used to detect changes in gene expression between CD8+ T cells cultured with and without the SKOV3 ovarian adenocarcinoma cell line. QRT-PCR was performed to determine glycolysis gene expression in CD8+ T cells from a transwell culturing system and OC patients. We also detected protein levels of glycolysis-related genes using Western blot analysis.
RESULTS: Comparing gene expression profiles revealed significant differences in expression levels of 1420 genes, of which 246 were up-regulated and 1174 were down-regulated. Gene Ontology and Kyoto Encyclopedia of Genes and Genomes analysis indicated that biological processes altered in CD8+ Treg are particularly associated with energy metabolism. CD8+ Treg cells induced by co-culture with SKOV3 had lower glycolysis gene expression compared to CD8+ T cells cultured alone. Glycolysis gene expression was also decreased in the CD8+ T cells of OC patients.
CONCLUSIONS: These findings provide a comprehensive bioinformatics analysis of DEGs in CD8+ T cells cultured with and without SKOV3 and suggests that metabolic processes may be a possible mechanism for CD8+ Treg induction.
© 2016 John Wiley & Sons Ltd.

Entities:  

Mesh:

Year:  2016        PMID: 27641758      PMCID: PMC6496584          DOI: 10.1111/cpr.12294

Source DB:  PubMed          Journal:  Cell Prolif        ISSN: 0960-7722            Impact factor:   6.831


  34 in total

1.  IL-16 as an anti-inflammatory cytokine in rheumatoid synovitis.

Authors:  P A Klimiuk; J J Goronzy; C M Weyand
Journal:  J Immunol       Date:  1999-04-01       Impact factor: 5.422

2.  Suppression of antitumor immunity by IL-10 and TGF-beta-producing T cells infiltrating the growing tumor: influence of tumor environment on the induction of CD4+ and CD8+ regulatory T cells.

Authors:  Andrew G Jarnicki; Joanne Lysaght; Stephen Todryk; Kingston H G Mills
Journal:  J Immunol       Date:  2006-07-15       Impact factor: 5.422

3.  Tracking global gene expression responses in T cell differentiation.

Authors:  Oriane Simeoni; Vincent Piras; Masaru Tomita; Kumar Selvarajoo
Journal:  Gene       Date:  2015-05-28       Impact factor: 3.688

4.  CD4+ CD25+ T cells with the phenotypic and functional characteristics of regulatory T cells are enriched in the synovial fluid of patients with rheumatoid arthritis.

Authors:  M Möttönen; J Heikkinen; L Mustonen; P Isomäki; R Luukkainen; O Lassila
Journal:  Clin Exp Immunol       Date:  2005-05       Impact factor: 4.330

Review 5.  T-regulatory cells: key players in tumor immune escape and angiogenesis.

Authors:  Andrea Facciabene; Gregory T Motz; George Coukos
Journal:  Cancer Res       Date:  2012-05-01       Impact factor: 12.701

6.  The role of CD8+CD28 regulatory cells in suppressing myasthenia gravis-associated responses by a dual altered peptide ligand.

Authors:  Hava Ben-David; Amir Sharabi; Molly Dayan; Michael Sela; Edna Mozes
Journal:  Proc Natl Acad Sci U S A       Date:  2007-10-23       Impact factor: 11.205

7.  Identification of a human CD8+ regulatory T cell subset that mediates suppression through the chemokine CC chemokine ligand 4.

Authors:  Simone A Joosten; Krista E van Meijgaarden; Nigel D L Savage; Tjitske de Boer; Frédéric Triebel; Annemieke van der Wal; Emile de Heer; Michèl R Klein; Annemieke Geluk; Tom H M Ottenhoff
Journal:  Proc Natl Acad Sci U S A       Date:  2007-05-02       Impact factor: 11.205

8.  CD8+ Foxp3+ regulatory T cells mediate immunosuppression in prostate cancer.

Authors:  Yukiko Kiniwa; Yoshihiro Miyahara; Helen Y Wang; Weiyi Peng; Guangyong Peng; Thomas M Wheeler; Timothy C Thompson; Lloyd J Old; Rong-Fu Wang
Journal:  Clin Cancer Res       Date:  2007-12-01       Impact factor: 12.531

9.  The beta2 integrin CD11c distinguishes a subset of cytotoxic pulmonary T cells with potent antiviral effects in vitro and in vivo.

Authors:  Marc Beyer; Hongwei Wang; Nina Peters; Sandra Doths; Cordula Koerner-Rettberg; Peter J M Openshaw; Jürgen Schwarze
Journal:  Respir Res       Date:  2005-07-12

10.  Generation of human CD8 T regulatory cells by CD40 ligand-activated plasmacytoid dendritic cells.

Authors:  Michel Gilliet; Yong-Jun Liu
Journal:  J Exp Med       Date:  2002-03-18       Impact factor: 14.307

View more
  5 in total

Review 1.  Immune regulation by CD8+ Treg cells: novel possibilities for anticancer immunotherapy.

Authors:  Shuping Zhang; Meng Wu; Fang Wang
Journal:  Cell Mol Immunol       Date:  2018-09       Impact factor: 11.530

Review 2.  Revisiting ovarian cancer microenvironment: a friend or a foe?

Authors:  Boyi Zhang; Fei Chen; Qixia Xu; Liu Han; Jiaqian Xu; Libin Gao; Xiaochen Sun; Yiwen Li; Yan Li; Min Qian; Yu Sun
Journal:  Protein Cell       Date:  2017-09-19       Impact factor: 14.870

3.  PD-1/PD-L1 blockade rescue exhausted CD8+ T cells in gastrointestinal stromal tumours via the PI3K/Akt/mTOR signalling pathway.

Authors:  Rui Zhao; Yinghan Song; Yong Wang; Yuqian Huang; Zhigui Li; Yaping Cui; Mengshi Yi; Lin Xia; Wen Zhuang; Xiaoting Wu; Yong Zhou
Journal:  Cell Prolif       Date:  2019-02-03       Impact factor: 6.831

Review 4.  Mitochondrial Dysfunction Pathway Alterations Offer Potential Biomarkers and Therapeutic Targets for Ovarian Cancer.

Authors:  Liang Shen; Xianquan Zhan
Journal:  Oxid Med Cell Longev       Date:  2022-04-20       Impact factor: 7.310

5.  Identification of Hypoxia Signature to Assess the Tumor Immune Microenvironment and Predict Prognosis in Patients with Ovarian Cancer.

Authors:  Chunyan Wei; Xiaoqing Liu; Qin Wang; Qipei Li; Min Xie
Journal:  Int J Endocrinol       Date:  2021-12-14       Impact factor: 3.257

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.